While the role of HGF/c-MET activation has been extensively studies and therapeutically targeted in solid tumors (Matsumoto et al., 2017), its involvement in hematological malignancies, including CLL, remains poorly understood. Here, HGF is linked to B-cell chronic lymphocytic leukemia.